Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CSCI

COSCIENS Biopharma Inc

Mar 13 • 04:00PM ET

3.11

Dollar change +0.42
Percentage change 15.61	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN GILD REGN VRTX BIIB BMY MRNA LLY INCY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-26.09	Insider Own	1.57%	Shs Outstand	3.12M	Perf Week	14.27%
Market Cap	9.70M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.07M	Perf Month	14.34%
Income	-18.56M	PEG	-	EPS next Q	-	Inst Own	8.92%	Short Float	0.27%	Perf Quarter	10.54%
Sales	4.33M	P/S	2.24	EPS this Y	-	Inst Trans	0.04%	Short Ratio	1.12	Perf Half Y	-22.25%
Book/sh	6.41	P/B	0.49	EPS next Y	-	ROA	-43.04%	Short Interest	0.01M	Perf Year	-59.08%
Cash/sh	6.41	P/C	0.49	EPS next 5Y	-	ROE	-80.20%	52W Range	2.38 - 11.10	Perf YTD	12.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-87.46%	52W High	-71.98%	Beta	1.30
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	154.37%	Gross Margin	37.30%	52W Low	30.67%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.46	EPS Y/Y TTM	-35.52%	Oper. Margin	-486.85%	RSI (14)	62.87	Volatility	15.22% 7.47%
Employees	21	Debt/Eq	0.08	Sales Y/Y TTM	-36.86%	Profit Margin	-428.43%	Recom	1.00	Target Price	60.00
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	45.74%	Payout	-	Rel Volume	89.60	Prev Close	2.69
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	62266.67%	Earnings	Nov 12 BMO	Avg Volume	7.54K	Price	3.11
SMA20	12.13%	SMA50	8.55%	SMA200	-26.97%	Trades		Volume	675,751	Change	15.61%

Mar-13-25 07:55AM	COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product (GlobeNewswire) +15.61%
Dec-23-24 07:45AM	COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization (GlobeNewswire)
Nov-12-24 07:30AM	COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs (GlobeNewswire) -10.18%
Oct-08-24 07:30AM	COSCIENS Biopharma Announces Change to Board of Directors (GlobeNewswire)
Oct-01-24 05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labbe as Director (GlobeNewswire)
05:30PM	Loading…
05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labb as Director (GlobeNewswire)
Sep-23-24 07:30AM	COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs (GlobeNewswire) -5.58%
Aug-27-24 07:30AM	COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency (GlobeNewswire) -32.42%
Aug-13-24 08:05AM	COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)

COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSCI

COSCIENS Biopharma Inc

Upgrade your FINVIZ experience